Oncolytics Biotech Inc T.ONC

Alternate Symbol(s): ONCY

Healthcare Biotechnology

Oncolytics Biotech Inc. is a biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to phase 3 licensure-enabling studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc

<< Previous

Bullboard Posts

Next >>

Post by CarbonWarrioron Nov 22, 2022 12:22pm

182 Views

Post# 35119046

Roche Deal for Pancretic Cancer Goblet???

A deal could be like this:

Just last month Roche paid this: 1 Billion
https://www.pharmaceutical-technology.com/news/hookipa-roche-cancer-immunotherapy/

Here Roche would have to pay much much more because Goblet results means that we are now a PIII company.

Okay Roche. Give us something now. The SP is very cheap this stock is vulnerable...
Even a low ball deal and we move to at least 500M in valuation i.e. close to 5 - 6$ range.

<< Previous

Bullboard Posts

Next >>

Mid-year review: How has gold been performing?